Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Washington: - FHCC Overlake — Bellevue, Washington
- Highline Medical Center-Main Campus — Burien, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Saint Elizabeth Hospital — Enumclaw, Washington
- Saint Francis Hospital — Federal Way, Washington
Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Providence Regional Cancer Partnership — Everett, Washington
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in Washington: - Providence Regional Cancer Partnership — Everett, Washington
- Providence Regional Medical Center Everett — Everett, Washington
- Northwest Cancer Specialists, P.C. — Vancouver, Washington
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Washington: - FHCC Overlake — Bellevue, Washington
- FHCC at EvergreenHealth — Kirkland, Washington
- Virginia Mason Medical Center — Seattle, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
- FHCC at Northwest Hospital — Seattle, Washington
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Washington: - Providence Regional Cancer System — Lacey, Washington
- Fred Hutchinson Cancer Research Center — Seattle, Washington
Phase 3 Recruiting Industry
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…
Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Washington: - Clinical Study Site — Spokane, Washington
- Clinical Study Site — Tacoma, Washington
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Washington: - Fred Hutchinson Cancer Center ( Site 0076) — Seattle, Washington
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Sites in Washington: - Benaroya Research Institute at Virginia Mason — Seattle, Washington
- University of Washington - Fred Hutchinson — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Washington: - University of Washington, Fred Hutchinson Cancer Center — Seattle, Washington
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Washington: - Wenatchee Hospitals and Clinics — Wenatchee, Washington
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, two-part trial in participants with FAP.
Sponsor: Recursion Pharmaceuticals Inc.
NCT ID: NCT05552755
Sites in Washington: - Benaroya Research Institute at Virginia Mason — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Washington: - Gynecology Oncology clinic at UW Medical Center - Montlake — Seattle, Washington
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Washington: - Fred Hutchinson Cancer Research Center — Seattle, Washington
Phase 2 Recruiting Industry
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
NCT ID: NCT06281678
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received t…
Sponsor: GlaxoSmithKline
NCT ID: NCT06885034
Sites in Washington: - GSK Investigational Site — Wenatchee, Washington
Phase 2 Recruiting Industry
This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with …
Sponsor: Stingray Therapeutics
NCT ID: NCT06589440
Sites in Washington: - Swedish — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.
Sponsor: TiumBio Co., Ltd.
NCT ID: NCT05784688
Sites in Washington: - Medical Oncology — Spokane, Washington
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and …
Sponsor: Xencor, Inc.
NCT ID: NCT05433142
Sites in Washington: - Xencor Investigative Site — Seattle, Washington
Phase 1 Recruiting Industry
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, an…
Sponsor: AstraZeneca
NCT ID: NCT06147037
Sites in Washington: - Research Site — Seattle, Washington
Phase 1 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or met…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06562192
Sites in Washington: - University Of Washington — Seattle, Washington
Phase 1 Recruiting Industry
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Sponsor: ALX Oncology Inc.
NCT ID: NCT07085091
Sites in Washington: - ALX Center 1 — Spokane, Washington
Phase 1 Recruiting Industry
Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC
Sponsor: Rgenta Therapeutics Inc
NCT ID: NCT06462183
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington